Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 - PubMed (original) (raw)
. 2006 Dec 1;66(23):11100-5.
doi: 10.1158/0008-5472.CAN-06-2554.
Denis R Patrick, Roberta S Batorsky, Maureen L Ho, Hieu T Do, Shu Yun Zhang, Rakesh Kumar, David W Rusnak, Andrew K Takle, David M Wilson, Erin Hugger, Lifu Wang, Florian Karreth, Julie C Lougheed, Jae Lee, David Chau, Thomas J Stout, Earl W May, Cynthia M Rominger, Michael D Schaber, Lusong Luo, Ami S Lakdawala, Jerry L Adams, Rooja G Contractor, Keiran S M Smalley, Meenhard Herlyn, Michael M Morrissey, David A Tuveson, Pearl S Huang
Affiliations
- PMID: 17145850
- DOI: 10.1158/0008-5472.CAN-06-2554
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
Alastair J King et al. Cancer Res. 2006.
Abstract
Oncogenic BRAF alleles are both necessary and sufficient for cellular transformation, suggesting that chemical inhibition of the activated mutant protein kinase may reverse the tumor phenotype. Here, we report the characterization of SB-590885, a novel triarylimidazole that selectively inhibits Raf kinases with more potency towards B-Raf than c-Raf. Crystallographic analysis revealed that SB-590885 stabilizes the oncogenic B-Raf kinase domain in an active configuration, which is distinct from the previously reported mechanism of action of the multi-kinase inhibitor, BAY43-9006. Malignant cells expressing oncogenic B-Raf show selective inhibition of mitogen-activated protein kinase activation, proliferation, transformation, and tumorigenicity when exposed to SB-590885, whereas other cancer cell lines and normal cells display variable sensitivities or resistance to similar treatment. These studies support the validation of oncogenic B-Raf as a target for cancer therapy and provide the first evidence of a correlation between the expression of oncogenic BRAF alleles and a positive response to a selective B-Raf inhibitor.
Similar articles
- Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA. Ouyang B, et al. Clin Cancer Res. 2006 Mar 15;12(6):1785-93. doi: 10.1158/1078-0432.CCR-05-1729. Clin Cancer Res. 2006. PMID: 16551863 - RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
Fan F, Feng L, He J, Wang X, Jiang X, Zhang Y, Wang Z, Chen Y. Fan F, et al. Carcinogenesis. 2008 Jun;29(6):1157-63. doi: 10.1093/carcin/bgn119. Epub 2008 May 29. Carcinogenesis. 2008. PMID: 18515281 - Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF. Wong H, et al. J Pharmacol Exp Ther. 2009 Apr;329(1):360-7. doi: 10.1124/jpet.108.148189. Epub 2009 Jan 15. J Pharmacol Exp Ther. 2009. PMID: 19147858 - Emerging Raf inhibitors.
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Expert Opin Emerg Drugs. 2009. PMID: 19715444 Review. - Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB. El-Nassan HB. Eur J Med Chem. 2014 Jan 24;72:170-205. doi: 10.1016/j.ejmech.2013.11.018. Epub 2013 Nov 27. Eur J Med Chem. 2014. PMID: 24424304 Review.
Cited by
- Targeting RAF dimers in RAS mutant tumors: From biology to clinic.
Yin H, Tang Q, Xia H, Bi F. Yin H, et al. Acta Pharm Sin B. 2024 May;14(5):1895-1923. doi: 10.1016/j.apsb.2024.02.018. Epub 2024 Feb 28. Acta Pharm Sin B. 2024. PMID: 38799634 Free PMC article. Review. - Pan-cancer analysis of SERPINE family genes as biomarkers of cancer prognosis and response to therapy.
Liu Y, Li X, Chen S, Zhu C, Shi Y, Dang S, Zhang W, Li W. Liu Y, et al. Front Mol Biosci. 2024 Jan 11;10:1277508. doi: 10.3389/fmolb.2023.1277508. eCollection 2023. Front Mol Biosci. 2024. PMID: 38274096 Free PMC article. - Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF Inhibitors.
Clayton J, Romany A, Matenoglou E, Gavathiotis E, Poulikakos PI, Shen J. Clayton J, et al. bioRxiv [Preprint]. 2024 Apr 17:2023.12.12.571293. doi: 10.1101/2023.12.12.571293. bioRxiv. 2024. PMID: 38168366 Free PMC article. Preprint. - An updated literature on BRAF inhibitors (2018-2023).
Maji L, Teli G, Raghavendra NM, Sengupta S, Pal R, Ghara A, Matada GSP. Maji L, et al. Mol Divers. 2024 Aug;28(4):2689-2730. doi: 10.1007/s11030-023-10699-3. Epub 2023 Jul 20. Mol Divers. 2024. PMID: 37470921 Review. - Mechanism and inhibition of BRAF kinase.
Gunderwala A, Cope N, Wang Z. Gunderwala A, et al. Curr Opin Chem Biol. 2022 Dec;71:102205. doi: 10.1016/j.cbpa.2022.102205. Epub 2022 Sep 5. Curr Opin Chem Biol. 2022. PMID: 36067564 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous